Enclomiphene is a nonsteroidal selective estrogen receptor modulator (SERM) that was first developed in the 1960s. It is the trans-isomer of clomiphene citrate, a drug that has been used for decades to treat female infertility.
Clomiphene citrate was found to be effective in increasing testosterone levels in men, but it also had a number of side effects, including visual disturbances and hot flashes. Enclomiphene was developed in an attempt to create a SERM with the same testosterone-boosting effects as clomiphene citrate, but with fewer side effects.
Enclomiphene was first tested in humans in the early 1970s. In early clinical trials, enclomiphene was shown to be effective in increasing testosterone levels and improving sperm quality in men with hypogonadism. However, the development of enclomiphene was discontinued due to concerns about its long-term safety.
In the early 2000s, interest in enclomiphene was renewed. This was due in part to the growing popularity of testosterone replacement therapy (TRT) and the increasing awareness of the potential risks of TRT. Enclomiphene was seen as a potential alternative to TRT that could provide the same testosterone-boosting benefits without the same risks.
A number of clinical trials of enclomiphene have been conducted in recent years. These trials have shown that enclomiphene is effective in increasing testosterone levels and improving sperm quality in men with hypogonadism. Enclomiphene has also been shown to be well-tolerated, with few side effects.
In 2014, enclomiphene was granted orphan drug status by the FDA for the treatment of male infertility. This status gives enclomiphene priority review during the FDA approval process.
Enclomiphene is still under investigation, but it has the potential to become a valuable new treatment for male hypogonadism and other conditions associated with low testosterone levels.
Future of enclomiphene
Enclomiphene is a promising new drug for the treatment of male hypogonadism and other conditions associated with low testosterone levels. It is well-tolerated and has few side effects. More research is needed to confirm its long-term safety and efficacy, but it has the potential to revolutionize the treatment of male hypogonadism.
One of the main advantages of enclomiphene over other treatments for male hypogonadism, such as testosterone replacement therapy (TRT), is that it stimulates the body’s own production of testosterone. TRT, on the other hand, provides testosterone from an external source. This can lead to a number of problems, such as suppression of the body’s natural testosterone production and infertility.
Enclomiphene also has fewer side effects than TRT. Some of the most common side effects of TRT include acne, hair loss, and prostate enlargement. Enclomiphene is generally well-tolerated, with few side effects.
Overall, enclomiphene is a promising new drug for the treatment of male hypogonadism and other conditions associated with low testosterone levels. It is well-tolerated and has few side effects. More research is needed to confirm its long-term safety and efficacy, but it has the potential to revolutionize the treatment of male hypogonadism.
Enclomiphene is a nonsteroidal selective estrogen receptor modulator (SERM) that is being investigated for the treatment of male hypogonadism and other conditions associated with low testosterone levels. It is well-tolerated and has few side effects. More research is needed to confirm its long-term safety and efficacy, but it has the potential to revolutionize the treatment of male hypogonadism.
